- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
U.S. Stem Cell Trial Treats First Patient
12 October 2010 11:14 am
The first approved U.S. clinical trial to use human embryonic stem cells to treat a disease has enrolled its first patient. Geron Corp., which is sponsoring the trial using stem cells for spinal cord injury, announced yesterday that the patient was treated at a hospital in Atlanta. Patients in the study will receive an injection of stem cells at the site of spinal cord damage within 2 weeks after the injury. The small trial is a safety study, but as The Washington Post notes, researchers will also test to see if they benefit from the therapy. The U.S. Food and Drug Administration approved the trial in January 2009 but later suspended it because of safety concerns; FDA lifted the hold in July.